An Open-label, Single-dose, Phase I Study to Assess the Pharmacokinetics and Safety of DBPR108 Tablets in Subjects With Mild, Moderate Hepatic Impairment Compared to the Control Subjects With Normal Hepatic Function
Latest Information Update: 14 Apr 2023
At a glance
- Drugs Prusogliptin (Primary)
- Indications Liver failure; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors CSPC ZhongQi Pharmaceutical Technology
- 10 Apr 2023 Status changed from recruiting to completed.
- 11 Jun 2021 Status changed from not yet recruiting to recruiting.
- 28 Apr 2021 New trial record